MELAS Syndrome: Mitochondrial Genetic Disorders


  • Muhamad Fathurrahman Zain Lampung University
  • Kevin Jeremia Purba Medical Student, Lampung University
  • Delisa Mutiara Nabila Medical Student, Lampung University
  • Takhfa Nur Asyifa Medical Student, Lampung University
  • Rani Himayani Bagian Ilmu Penyakit mata, Fakultas Kedokteran, Universitas Lampung



Genetic disorder, MELAS, Treatment


MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) is an inherited mitochondrial genetic disorder. Paternal mitochondria are present only in the sperm tailpiece due to a mutation in the tRNA in the mitochondrial gene MTTL1. MELAS is the most common mitochondrial disease with an incidence prevalence of 1 in 4000. MELAS syndrome is a multi-organ disease with a wide variety of manifestations including stroke-like episodes, dementia, epilepsy, lactic acidosis, myopathy, recurrent headaches, hearing loss, diabetes, and short stature. Individuals with the MELAS syndrome often present with more than one initial clinical manifestation. The diagnosis can be made with Hirano’s criteria for MELAS. The diagnostic criteria for MELAS must include the following events: (1) signs of encephalopathy, often with dementia and seizures, (2) episodes similiar to stroke (stroke-like episodes) in young age, and (3) biochemical evidence of mitochondrial dysfunction such as lactic acidosis or RRF in muscle biopsy. There is no specific treatment for MELAS syndrome, but most of the treatment for MELAS is symptomatic and involves multidiscipline such as neurologists, cardiologists, endocrinologists, audiologists, ophthalmologists, physical and occupational therapy and psychology, considering that MELAS syndrome can cause dysfunction of several organ.

Author Biographies

Muhamad Fathurrahman Zain, Lampung University



Kevin Jeremia Purba, Medical Student, Lampung University



Delisa Mutiara Nabila, Medical Student, Lampung University



Takhfa Nur Asyifa, Medical Student, Lampung University



Rani Himayani, Bagian Ilmu Penyakit mata, Fakultas Kedokteran, Universitas Lampung




El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Molecular Genetics and Metabolism. 2015;116(1-2), 4–12.

S. DiMauro, M. Hirano, MELAS, in: R.A. Pagon, M.P. Adam, H.H. Ardinger, et al., (Eds.), GeneReviews®, University of Washington, Seattle, 2013 [Internet].

Pia S, Lui F. Melas Syndrome. In StatPearls [Internet]. StatPearls Publishing. 2021.

Ikeda T, Osaka H, Shimbo H, Tajika M, Yamazaki M, Ueda A, Murayama K, Yamagata T. Mitochondrial DNA 3243A>T mutation in a patient with MELAS syndrome. Hum Genome Var. 2018;5:25.

Niedermayr K, Pölzl G, Scholl-Bürgi S, Fauth C, Schweigmann U, Haberlandt E, Albrecht U, Zlamy M, Sperl W, Mayr JA, Karall D. Mitochondrial DNA mutation "m.3243A>G"-Heterogeneous clinical picture for cardiologists ("m.3243A>G": A phenotypic chameleon). Congenit Heart Dis. 2018;13(5):671-677.

Koga Y, Povalko N, Inoue E, Nakamura H, Ishii A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, Fujii K. Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. J Neurol. 2018;265(12):2861-2874.

Anglin RE, Garside SL, Tarnopolsky MA, Mazurek MF, & Rosebush PI. The psychiatric manifestations of mitochondrial disorders: a case and review of the literature. The Journal of clinical psychiatry, 2012;73(4), 506–512.

El-Hattab, A. W., Almannai, M., & Scaglia, F. 2001. MELAS. In M. P. Adam (Eds.) et. al., GeneReviews®. University of Washington, Seattle.

Scarpelli M, Zappini F, Filosto M, Russignan A, Tonin P, Tomelleri G. 2012. Mitochondrial sensorineural hearing loss: a retrospective study and a description of cochlear implantation in a MELAS patient, Genet. Res. Int. 287432.

Kent TA. MELAS - Mitochondrial Encephalomyopathy, Lactic Acidosis, Strokelike Episodes Overview of MELAS [internet]. Medscape; 2021 [disitasi tanggal 28 desember 2022] Tersedia dari

Lorenzoni PJ, Werneck LC, Kay CSK, Silvado CES, Scola RH. When should MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes) Be The Diagnosis?. Arq Neuropsiquiatr. 2015;73(11):959-967

Fan HC, Lee HF, Yue CT, Chi CS. Clinical Characteristics of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes. Life. 2021; 11(111): 1-25.

Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG, DeVivo DC et al.. Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord.1992;2(2):125-35. doi:10.1016/0960-8966(92)90045-8

Yatsuga S, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T et al.. MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta. 2012;1820(5):619-24. doi:10.1016/j.bbagen.2011.03.015

Alston CL., Rocha MC, Lax NZ, Turnbull DM,Taylor RW. The genetics and pathology of mitochondrial disease. J. Pathol. 2017, 241, 236–250.

Ng, Y.S.; Bindoff, L.A.; Gorman, G.S.; Horvath, R.; Klopstock, T.; Mancuso, M.; Martikainen, M.H.; McFarland, R.; Nesbitt, V.; Pitceathly, R.D.S.; et al. Consensus-based statements for the management of mitochondrial stroke-like episodes. Wellcome Open Res. 2019, 4, 201



How to Cite

Zain, M. F., Purba, K. J., Nabila, D. M., Asyifa, T. N., & Himayani, R. (2023). MELAS Syndrome: Mitochondrial Genetic Disorders. Medical Profession Journal of Lampung, 13(1), 128-135.




Most read articles by the same author(s)

1 2 3 4 5 6 > >>